1	SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in
2	Lombardy, Italy
3	
4	Maria Teresa Sandri ¹¹ , Elena Azzolini ¹¹ , Valter Torri ² , Sara Carloni ³ , Chiara Pozzi ¹ , Michela
5	Salvatici ¹ , Michele Tedeschi ¹ , Massimo Castoldi ⁵ , Alberto Mantovani ^{1,3,4} and Maria Rescigno ^{1,3*}
6	
7	¹ Humanitas Clinical and Research Center – IRCCS, Rozzano – Milan, Italy
8	² Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milano, Italy
9	³ Humanitas University Department of Biomedical Sciences, Pieve Emanuele – Milan, Italy
10	⁴ The William Harvey Research Institute, Queen Mary University of London, London, UK
11	⁵ Humanitas Gavazzeni and Castelli, Bergamo, Italy
12	
13	These authors contributed equally
14	
15	
16	* Corresponding author
17	E-mail: maria.rescigno@hunimed.eu
18	

19 Abstract

Lombardy is the Italian region most affected by COVID-19. We tested the presence of plasma anti-20 21 SARS-CoV-2 IgG antibodies in 3985 employees across 7 healthcare facilities in areas of Lombardy 22 with different exposure to the SARS-CoV-2 epidemic. Subjects filled a questionnaire to self-report 23 on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to 24 COVID-infected individuals. We show that the number of individuals exposed to the virus depended 25 on the geographical location of the facility, ranging between 3 and 43%, consistent with the spatial 26 variation of COVID-19 incidence in Lombardy, and correlated with family contacts. We observed a 27 higher prevalence of females than males positive for IgG, however the level of antibodies was similar, 28 suggesting a comparable magnitude of the response. IgG positivity among smokers was lower (7.4%)vs 13.5%) although without difference in IgG plasma levels. We observed 11.9% of IgG positive 29 30 asymptomatic individuals and another 23.1% with one or two symptoms. Interestingly, among the IgG positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 31 32 infected, indicating that these symptoms are strongly associated to COVID-19. The plasma level of 33 IgG inversely correlated with anti-pneumococcal vaccination. In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the 34

In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the
 geographical exposure to the virus and primarily to family rather than hospital exposure.

37 Introduction

38 Lombardy has been the Italian region most affected by SARS-Cov-2 infection with more than 80,000 from the outbreak and a mortality rate of nearly 18% (as of May 8th, 39 cases 40 https://utils.cedsdigital.it/coronavirus/#regioni1). Only symptomatic individuals have been tested by 41 RT-PCR to detect SARS-CoV-2, and hence the spreading of the virus, particularly in the 42 asymptomatic population, is unknown. Detection of viral RNA is not very sensitive in cases of low 43 viral load, when patients with negative RT PCR test convert to positive in few days, or when COVID-19 is highly suspected by the result of chest CT¹⁻⁶. It is just a snapshot of the exact moment of the 44 infection. Hence, unless being continuously monitored by viral testing, the asymptomatic individuals' 45 46 infected state may be missed.

47 A retrospective way to assess viral spread is via the analysis of an immune response that can be 48 detected through the development of immunoglobulins ⁷. Indeed, almost the totality (>95%) of 49 laboratory-confirmed COVID-19 showed seroconversion even using different methodologies and antibody isotypes (ELISA, EIA, anti-IgM, anti-IgG or anti-IgA)⁷⁻¹¹. Interestingly, the dynamic of the 50 51 immune response to SARS-CoV-2 is very peculiar and patient dependent. IgM for instance, which 52 should be the first type of immunoglobulins to appear under normal circumstances, are detected before, concomitant or even after IgGs, or do not appear at all ^{7,12}. This suggests that differently from 53 54 other infectious diseases, in SARS-CoV-2 infection, IgG is a more reliable marker for seroconversion 55 than IgM.

There is evidence that IgG analysis allowed to detect viral RNA negative asymptomatic relatives of COVID-19 patients ⁷, suggesting that anti-SARS-CoV-2 IgG may be used as a diagnostic tool to detect the incidence of asymptomatic infections even in cases of impossibility of viral detection. Based on these assumptions, we tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in nearly 4000 (3985) employees of 7 different healthcare facilities, one including a research center and

a University, located across the Lombardy region in areas with different exposure to the epidemic
(Milan, Rozzano, Varese, Castellanza and Bergamo (the city most affected by the pandemic per
number of individuals)). All of the analyzed hospitals drastically reduced their routine practice and,
except for Humanitas Medical Care, which is a point of care, they were all dedicated to COVID-19
during the time of observation.

66

67 **Results**

68 **Study population**

Recruitment was on a voluntary basis: it started on April 28th and more than 65% of employees 69 70 participated as of May 16th, 2020 (clinicaltrial.gov NCT04387929). An international medical school 71 (Humanitas University, Pieve Emanuele (MI)) and 6 different hospitals participated to the study: 72 Istituto Clinico Humanitas (ICH), Rozzano (MI); Humanitas Gavazzeni, Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini (HMD), Castellanza (VA); Humanitas Medical Care 73 74 (HMC), Varese (VA); Humanitas San Pio X, Milano (MI). The individuals were healthcare 75 professionals (physicians (16.5%), surgeons (7.2%) anesthesiologists (2.8%), physiotherapists 76 (1.8%), nurses (25.4%)), technicians (4.4%), students (0.7%), researchers/academics (3.1%), other 77 roles, including administrative staff (7.9%), biologists (1.3%) etc.. 66.8% were females and 33.2% 78 males, median age 42 yo (21-86 yo) (Supplementary Table S1). The distribution of the healthcare 79 workers participating to the study among the different hospitals was very similar except for HMC, a 80 point of care, where the proportion of workers differs from that of the other hospitals, and for ICH 81 which is the only site where researchers work (Supplementary Fig. S1). Besides this, we did not 82 observe major differences in the voluntary participation of the different professionals across sites.

Subjects filled a questionnaire reporting whether they had COVID-associated symptoms, including
 fever, dry cough, asthenia, soreness and muscle pain, runny nose, sore throat, gastrointestinal

85 symptoms (including vomiting, nausea, diarrhea), conjunctivitis, pneumonia, severe acute respiratory syndrome, anosmia/dysgeusia from February 1st to the time of questionnaire filling. They also 86 87 reported on body mass index (BMI), co-morbidities (hypertension, heart disease or diabetes, 88 immunosuppression), smoking, vaccinations, regular or smart-working, the frequency of home exits 89 for non-work related reasons and the exposure to COVID-infected individuals. With the exception of HMC, which being a point of care closed down at lockdown (officially started on March 9th), during 90 91 the pandemic and in the period of observation, most of routine practice was interrupted, and the 92 majority of physician and non-physician healthcare professionals worked in COVID-dedicated areas 93 independent on the location of the hospital (for instance at ICH, 8 out of 20 wards were transformed 94 into COVID treatment wards (330 beds), and 2 into semi-intensive care units, while the intensive care 95 units (ICU) capacity doubled (60 beds)). All of the personnel working in the emergency room or 96 customer care had to wear obligatory PPE from February 1st at Castelli and Gavazzeni, from February 23rd at ICH, and from March 3rd everywhere in the hospital. Administrative staff workers stopped 97 98 working in the hospital at the beginning of lockdown and worked from home. Customer service and 99 research personnel worked one or two days a week at the sites and the rest of the time from home.

100

101 Frequency of IgG positivity and correlation with geographical area

Anti-S1 and anti-S2 SARS-CoV-2 IgG specific antibodies were detected via an indirect chemiluminescence immunoassay. According to kit manufacturer, the test discriminates among negative (<12AU/mL; with 3.8 as the limit of IgG detection), equivocal (12.0 – 15.0 AU/mL) and truly positive (>15.0 AU/mL) subjects. Of 3985 enrolled subjects, 3462 (87%) were negative, 76 (2%) equivocal and 447 (11%) positive (which together with equivocal summed up to 523 (13%)) (Supplementary Table S1). We decided to group together equivocal and truly positive subjects as they behaved very similarly both as separate groups or as grouped together (Positive - IgG \geq 12.0

AU/ml) in subsequent analyses (for instance in correlation with the number of symptoms, as shownin Supplementary Fig. S2).

111 The number of individuals exposed to the virus reflected the geographical area where the healthcare 112 facility was located (Fig. 1). Two hospitals based in Bergamo (Humanitas Gavazzeni and Castelli) 113 were the most affected as between 35 and 43 % of the subjects was IgG positive. In the other sites 114 the frequency of IgG positivity ranged between 3% (HMC) and 9% (ICH) (Supplementary Table S2). 115 We applied a hierarchical (multilevel) model adjusting for clustering of individuals within healthcare 116 facilities when assessing overall relationships between locations, professional status and the analyzed 117 variables. Humanitas Gavazzeni in Bergamo was significantly different from all other facilities 118 except for Castelli in Bergamo (Table 1 and Supplementary Fig. S3, p<0.0001,OR and 95%CI 119 indicated in the table). Interestingly, HMC and HMD which had the lowest incidence of IgG positive 120 individuals (3% and 3.8%, respectively), are located in Varese, which is one of the less COVID-19 121 affected province in Lombardy (https://www.lombardianotizie.online/coronavirus-casi-lombardia/). 122 In agreement, the percentage of patients hospitalized for COVID-19 was higher in Bergamo at

123 Gavazzeni (56%), intermediate in Milan at ICH (36%) and low in Varese at HMD (10%) (not shown).

Table 1 Logistic analysis for site effect				
Comparison	Odds ratio estimates	Lower 95% Cl	Upper 95% Cl	p-value
Humanitas Rozzano (ICH)	0.181	0.146	0.226	<.0001
Humanitas University (HU)	0.156	0.062	0.396	
Humanitas Medical Care (HMC)	0.057	0.014	0.234	
Humanitas San Pio X	0.126	0.074	0.215	
Humanitas Mater Domini (HMD)	0.073	0.041	0.131	
Humanitas Castelli	1.384	0.943	2.032	
Humanitas Gavazzeni - ref	1.00			

124

126 Frequency of IgG positivity and correlation with gender, BMI and smoking

127 IgG positivity (≥12 AU/mL) was different between males (11.4%) and females (14%)

128 (Supplementary Table S1), and, as shown in Table 2a, this difference was retained in the multilevel

logistic analysis (OR=0.73; 95%CI 0.57-0.94, p=0.016). Thus, the observed effect was associated to

- 130 a difference in gender sensitivity to infection or to the ability to mount an antibody response rather
- 131 than to a bias of the recruitment itself.
- 132 Interestingly, IgG positivity among smokers was lower (7.4% vs 13.5%) (OR=0.45; 95%CI 0.34-
- 133 0.60, *p*<0.0001, Supplementary Fig. S4) confirming the trend effect observed with the multilevel
- 134 logistic analysis (OR=0.48; 95%CI 0.38-0.61, p<0.0001, Table 2a). On the contrary, there was no
- 135 statistically significant difference according to BMI (Table 2a).

Table 2a Multilevel Logistic model for age, gender and their interaction, smoking habits, BMI									
Comparison	Odds ratio estimates	Lower 95% Cl	Upper 95% Cl	p-value					
Physician vs Other Role	1.10	0.79	1.53						
Surgeon vs Other Role	1.10	0.71	1.71						
Anesthesiologist vs Other Role	0.49	0.22	1.08						
Physiotherapist vs Other Role	1.17	0.56	2.46						
Nurse vs Other Role	1.16	0.87	1.55						
Researcher vs Other Role	0.94	0.47	1.90	0.5039					
Biologist vs Other Role	0.69	0.20	2.37						
Student vs Other Role	1.07	0.29	3.95						
Radiology Technician vs Other Role	0.53	0.25	1.13						
Lab. Technician vs Other Role	0.75	0.31	1.86						
Staff vs Other Role	1.04	0.67	1.61						
Smoking (Number of cigarettes/day)	0.48	0.38	0.61	<.0001					
Age >60 vs ≤60	0.35	0.15	0.83	0.0166					
Gender male vs female	0.73	0.57	0.94	0.0158					
Interaction Age*Gender	2.98	1.08	8.21	0.0352					
BMI	1.11	0.98	1.26	0.1127					

136

138 Frequency of IgG positivity and correlation with age

139 We then evaluated whether there was a difference in the positivity to IgG according to age. We found 140 that there was a Gaussian distribution of the number of IgG positive (≥12 AU/mL) individuals across 141 the age range (Fig. 2a), but then when analyzing the frequency of positivity at the different age ranges we observed an age dependent reduction of IgG positive individuals (Fig. 2b). However, this age-142 143 dependency was primarily due to the female rather than the male population, particularly for subjects 144 either young (20-40 yo) or older than 60 yo (test for heterogeneity of trend effect age between male 145 and female p=0.0024 Fig. 2b). In older than 60 vo, IgG positivity dropped from 12% in males to 5% 146 in females (Table 2a and Fig. 2b). This indicates that females are more likely to be infected - or to 147 induce an IgG response - when young, and less likely at ages higher than 60 yo.

148

149 Frequency of IgG positivity and correlation with viral positivity at time of testing

150 Following the guidelines of the national health system, all 523 subjects with IgG \geq 12 AU/ml 151 underwent a rinopharyngeal swab for SARS-CoV-2 RNA viral detection. We found that 39 (7.6%) 152 individuals resulted positive for viral RNA detection (Table 3). However, in 31 of these (79.5%), the 153 subjects tested negative for at least one of the genomic sequences of the three SARS-CoV-2 gene 154 targets: E, RdRp and N. To rule out that the negative population (3.8<IgG<12 AU/mL) comprised 155 individuals in the early phases of viral infection, a sample of 283 (35.4%) individuals underwent a 156 rinopharyngeal swab for SARS-CoV-2 RNA viral detection. All of them resulted negative to the swab 157 confirming the negativity of the test below 12 AU/mL (Table 3).

Table 3 Rinopharyngeal swab positivity in relation to IgG positivity														
		Rinopharyngeal swab results												
	Total		Negative			Positive low load				Positiv	'e	Positive low load + Positive		
	N	% of total	% of level	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	
IgG results														
Negative (3.8 <igg<12au ml)<="" td=""><td>283</td><td>35.4</td><td>283</td><td>100.0</td><td>37.2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></igg<12au>	283	35.4	283	100.0	37.2									
Equivocal (12÷15AU/mL)	75	9.4	70	93.3	9.2	3	4.0	9.7	2	2.7	25.0	5	6.7	12.8
Truly Positive (>15AU/mL)	441	55.2	407	92.3	53.6	28	6.3	90.3	6	1.4	75.0	34	7.7	87.2
Positive (≥12AU/mL)	516	64.6	477	92.4	62.8	31	6.0	100.0	8	1.6	100.0	39	7.6	100.0
Total	799	100.0	760	95.1	100.0	31	3.9	100.0	8	1.0	100.0	39	4.9	100.0

159

160 Frequency of IgG positivity and correlation with professional status

161 We then evaluated the proportion of IgG positive individuals ($\geq 12 \text{ AU/mL}$) across the different 162 professional workers and found that there was no statistically significant difference when taking into 163 account age, gender and their interaction, smoking habits, BMI and location (Table 2a) even though 164 some professionals worked from home from the beginning of lockdown (such as the administrative 165 staff), suggesting that their exposure to the virus was not occurring at work. We thus assessed which 166 could have been the major driver of transmission of the virus on the basis of the self-reported 167 questionnaire. We found heterogeneity of IgG positivity among drivers (p < 0.0001). Compared with group referring no contact, IgG positivity correlated most with family contacts (OR=4.73; 95%CI 168 169 2.93-7.65), and not with either a colleague or a patient, suggesting that this was likely the major cause 170 of viral exposure (Tables 4a-b). This finding is in line with a recent report on testing the serology of 171 healthcare workers and their families ¹³.

Table 4a Associatio		IgG results										
	То	otal	Negativ al (<12AU/r				Truly P	Positive U/mL)	Positive (≥12AU/mL)			
	N	% of total	N	%	N	%	N	%	N	%		
Contagion Modality												
None	1073	27.0	1010	94.1	11	1.0	52	4.8	63	5.9		
Colleague	853	21.5	740	86.8	20	2.3	93	10.9	113	13.2		
Patient	1599	40.2	1346	84.2	31	1.9	222	13.9	253	15.8		
Family member	138	3.5	95	68.8	7	5.1	36	26.1	43	31.2		
Other	310	7.8	262	84.5	7	2.3	41	13.2	48	15.5		
Total	3973	100.0	3453	86.9	76	1.9	444	11.2	520	13.1		

172

Table 4b Summary measures of association of contacts with IgG positivity								
Contagion Modality	Odds ratio	9!	5% CI					
None	Ref							
Colleague	1.59	1.11	2.27					
Patient	1.83	1.29	2.60					
Family member	4.73	2.93	7.65					
Other	2.05	1.32	3.18					
P value (Wald test)			<0.0001					
Multilevel logistic analysis, considering subjects nested in the hospital site. Adjusted for gender, BMI, smoking habits.	or role, age (c	ut off=	60 years)					

173

174 Frequency of IgG positivity and correlation with symptoms, comorbidities and vaccinations

175 We then evaluated whether there was a correlation between the number and typology of self-reported symptoms and the frequency of antibody response both as number of individuals (Fig. 3a and 3b) and 176 177 as percentage on the whole population (Fig. 3c and 3d). As shown in Figure 3, when analyzing 178 individuals deemed to be positive on the basis of the amount of IgG ($\geq 12 \text{ AU/mL}$) we observed a two 179 phases decay: first a similar frequency (a) or number (c) of subjects with 0 to 7 concomitant 180 symptoms, and then a drop of individuals at higher number of concomitant symptoms. This 181 distribution followed a sigmoidal, four parameter logistic curve whereby X is the number of

- 182 symptoms ($R^2=0.97$). By contrast, in the population with IgG <12 AU/mL we found a higher number
- 183 (b) or frequency (d) of individuals with 0, 1 or 2 symptoms and the distribution was following an
- exponential curve (R²=0.9975). The multilevel logistic analysis showed that, besides pneumonia, 184
- 185 among the symptoms, fever, anosmia/dysgeusia (loss of smell or taste) and chest pain were those that
- 186 best characterized the IgG positive population, particularly when collated (Table 2b).

Table 2b Multilevel Logistic model for symptoms adjusted for professional status, age, gender and their interaction, smoking habits, BMI									
Comparison	Odds ratio estimates	Lower 95% Cl	Upper 95% Cl	p-value					
Fever	5.79	3.58	9.36	<.0001					
Low-grade Fever	1.41	0.86	2.33	0.1735					
Cough	1.08	0.69	1.71	0.7266					
Sore Throath/Runny nose	0.93	0.61	1.42	0.7332					
Muscle pain	1.31	0.83	2.06	0.2453					
Asthenia	0.92	0.57	1.47	0.7263					
Anosmia/Dysgeusia	11.51	7.06	18.77	<.0001					
Gastrointestinal disorders	0.77	0.49	1.18	0.2299					
Conjunctivitis	1.35	0.77	2.36	0.2887					
Dyspnea	1.14	0.64	2.06	0.6539					
Chest pain	2.17	1.26	3.74	0.0055					
Tachycardia	0.64	0.38	1.09	0.0999					
Pneumonia	9.00	1.34	60.66	0.0240					

187

188 Indeed, dividing the population according to the number of symptoms, IgG positivity increased from 189 11.9% in the absence of symptoms to 42.8% in the presence of 5 symptoms or more (Table 5), and 190 the value of the AUC derived by the multivariable model was 79%, while the combination of just 191 fever versus anosmia/dysgeusia had an AUC of 78% (Supplementary Fig. S5). 81.2% of individuals 192 presenting both anosmia/dysgeusia and fever resulted SARS-CoV-2 infected. The sensitivity, 193 specificity and positive Likelihood ratio of anosmia/dysgeusia and fever were 25.6%, 99.1% and 194 28.6, respectively (Supplementary Table S3).

195 These results indicate that there are symptoms that best characterize the paucisymptomatic COVID-

196 19 population and that when individuals present with fever and anosmia/dysgeusia they are likely to

197 have SARS-CoV-2 infection.

Comorbidities (in particular cardiovascular diseases and metabolic syndrome) have been associated to a worse prognosis of COVID-19 patients ¹⁴. Hence we wanted to assess whether the presence of comorbidities correlated with a different incidence of IgG positivity. However, when we analyzed if there was any correlation between IgG positivity and comorbidities, we could not detect any (Supplementary Tables S4a and S4b). The same was true for the number or type of vaccination (flu, pneumococcus, tuberculosis or other vaccines) (Supplementary Tables S5a and S5b).

Table 5 Association of syr	nptom	s with	lgG p	ositivi	ty									
								lgG re	sults					
	Total			Negative (<12AU/mL)			Equivocal (12÷15AU/mL)			Positiv U/mL)	'e	Positive (≥12AU/mL)		
	N	% of total	N	% of level	% of total	Ν	% of level	% of total	N	% of level	% of total	Ν	% of level	% of total
Fever														
No	3488	87.5	3179	91.1	91.8	56	1.6	73.7	253	7.3	56.6	309	8.9	59.1
Yes	497	12.5	283	56.9	8.2	20	4.0	26.3	194	39.0	43.4	214	43.1	40.9
Low-grade Fever														
No	3557	89.3	3149	88.5	91.0	63	1.8	82.9	345	9.7	77.2	408	11.5	78.0
Yes	428	10.7	313	73.1	9.0	13	3.0	17.1	102	23.8	22.8	115	26.9	22.0
Cough														
No	3074	77.1	2750	89.5	79.4	57	1.9	75.0	267	8.7	59.7	324	10.5	62.0
Yes	911	22.9	712	78.2	20.6	19	2.1	25.0	180	19.8	40.3	199	21.8	38.0
Sore Throat/Runny nose														
No	2687	67.4	2391	89.0	69.1	50	1.9	65.8	246	9.2	55.0	296	11.0	56.6
Yes	1298	32.6	1071	82.5	30.9	26	2.0	34.2	201	15.5	45.0	227	17.5	43.4
Muscle pain														
No	2957	74.2	2707	91.5	78.2	42	1.4	55.3	208	7.0	46.5	250	8.5	47.8
Yes	1028	25.8	755	73.4	21.8	34	3.3	44.7	239	23.2	53.5	273	26.6	52.2
Asthenia														
No	3237	81.2	2948	91.1	85.2	43	1.3	56.6	246	7.6	55.0	289	8.9	55.3
Yes	748	18.8	514	68.7	14.8	33	4.4	43.4	201	26.9	45.0	234	31.3	44.7

Table 5 Association of sy	mptom	s with	lgG p	ositivi	ty										
					-			lgG re	sults						
	Тс	otal		Negative (<12AU/mL)			Equivocal (12÷15AU/mL)			Truly Positive (>15AU/mL)			Positive (≥12AU/mL)		
	N	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	
Anosmia/Dysgeusia															
No	3617	90.8	3348	92.6	96.7	46	1.3	60.5	223	6.2	49.9	269	7.4	51.4	
Yes	368	9.2	114	31.0	3.3	30	8.2	39.5	224	60.9	50.1	254	69.0	48.6	
Gastrointestinal disorders															
No	3165	79.4	2812	88.8	81.2	52	1.6	68.4	301	9.5	67.3	353	11.2	67.5	
Yes	820	20.6	650	79.3	18.8	24	2.9	31.6	146	17.8	32.7	170	20.7	32.5	
Conjunctivitis															
No	3583	89.9	3145	87.8	90.8	64	1.8	84.2	374	10.4	83.7	438	12.2	83.7	
Yes	402	10.1	317	78.9	9.2	12	3.0	15.8	73	18.2	16.3	85	21.1	16.3	
Dyspnea															
No	3726	93.5	3291	88.3	95.1	67	1.8	88.2	368	9.9	82.3	435	11.7	83.2	
Yes	259	6.5	171	66.0	4.9	9	3.5	11.8	79	30.5	17.7	88	34.0	16.8	
Chest pain															
No	3664	91.9	3235	88.3	93.4	62	1.7	81.6	367	10.0	82.1	429	11.7	82.0	
Yes	321	8.1	227	70.7	6.6	14	4.4	18.4	80	24.9	17.9	94	29.3	18.0	
Tachycardia															
No	3553	89.2	3112	87.6	89.9	62	1.7	81.6	379	10.7	84.8	441	12.4	84.3	
Yes	432	10.8	350	81.0	10.1	14	3.2	18.4	68	15.7	15.2	82	19.0	15.7	
Pneumonia															
No	3951	99.1	3457	87.5	99.9	75	1.9	98.7	419	10.6	93.7	494	12.5	94.5	
Yes	34	0.9	5	14.7	0.1	1	2.9	1.3	28	82.4	6.3	29	85.3	5.5	
Other symptoms															
No	3828	96.1	3341	87.3	96.5	71	1.9	93.4	416	10.9	93.1	487	12.7	93.1	
Yes	157	3.9	121	77.1	3.5	5	3.2	6.6	31	19.7	6.9	36	22.9	6.9	
Number of symptoms															
0 symptoms	1380	34.6	1318	95.5	38.1	11	0.8	14.5	51	3.7	11.4	62	4.5	11.9	
1 symptoms	814	20.4	758	93.1	21.9	10	1.2	13.2	46	5.7	10.3	56	6.9	10.7	
2 symptoms	582	14.6	517	88.8	14.9	11	1.9	14.5	54	9.3	12.1	65	11.2	12.4	
3 symptoms	411	10.3	350	85.2	10.1	10	2.4	13.2	51	12.4	11.4	61	14.8	11.7	
4 symptoms	256	6.4	201	78.5	5.8	8	3.1	10.5	47	18.4	10.5	55	21.5	10.5	
5 or more symptoms	542	13.6	318	58.7	9.2	26	4.8	34.2	198	36.5	44.3	224	41.3	42.8	
Fever and anosmia/dysgeusia															
No	3285	82.4	3096	94.2	89.4	39	1.2	51.3	150	4.6	33.6	189	5.8	36.1	

Table 5 Association of symptoms with IgG positivity														
		IgG results												
	Тс	otal	Negative (<12AU/mL)			Equivocal (12÷15AU/mL)			Truly Positive (>15AU/mL)			Positive (≥12AU/mL)		
	N	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total	N	% of level	% of total
Anosmia/dysgeusia	203	5.1	83	40.9	2.4	17	8.4	22.4	103	50.7	23.0	120	59.1	22.9
Fever	332	8.3	252	75.9	7.3	7	2.1	9.2	73	22.0	16.3	80	24.1	15.3
Fever and anosmia/dysgeusia	165	4.1	31	18.8	0.9	13	7.9	17.1	121	73.3	27.1	134	81.2	25.6
Total	3985	100.0	3462	86.9	100.0	76	1.9	100.0	447	11.2	100.0	523	13.1	100.0

²⁰⁵

206

207 IgG plasma levels and population characteristics

The frequency of IgG positive (≥12 AU/mL) individuals clearly reflected the increased exposure to 208 209 the virus across the analyzed geographical areas, correlated with COVID-19-related symptoms and 210 showed a higher proportion of positivity within young females and non-smoker subjects. However, 211 an advantage of using a quantitative assay for IgG testing is that it is also possible to assess the 212 magnitude of the immune response. Hence, we analyzed the data also in relation to IgG plasma levels. First, we assessed whether the level of plasma IgG correlated with positivity to the rinopharyngeal 213 214 swab. To take into account a possible temporal confounding factor of symptoms detection and 215 serological test, we compared the IgG plasma levels of swab positive or swab negative individuals 216 with that of the ascertained COVID-19 population (between the months of March and April). We 217 could not detect any statistically significant difference among IgG \geq 12 subjects with rinopharyngeal 218 swab positive or negative and the COVID-19 populations, suggesting that the positivity to the swab 219 does not correlate with a higher IgG plasma level (Fig. 4a). However, we observed that physicians 220 (including anesthesiologists and physiotherapists) had a higher level of plasmatic IgG as confirmed 221 by statistically different odds ratios (Supplementary Table S6, p=0.02 and odds ratios in 222 Supplementary Fig. S6).

224 IgG plasma levels BMI, gender and smoking

225 As we observed a higher proportion of positivity (IgG>12 AU/mL) within females that may indicate 226 either a higher exposure to the virus, a higher incidence of infection or a higher ability to mount an 227 immune response, we evaluated whether this difference was paralleled by increased IgG plasma 228 levels. We found out that there was no difference between IgG plasma levels of males versus females, 229 suggesting a similar magnitude of the immune response (Fig. 4b, Supplementary Table S6). However, 230 when assessing a difference of IgG plasma levels across age ranges, there was a trend towards an 231 increased level of plasma IgG towards the older age (p = 0.0002, total; p = 0.0085, females; p =232 0.008, males) (Fig. 4c). The difference of IgG response between females and males in relation to age 233 remains quite intriguing and we still have to understand its relevance with the higher incidence of COVID-19 in males ¹⁵. Interestingly, while smoking seemed to inversely correlate with the frequency 234 235 of IgG positive individuals, it did not have any effect on IgG plasma levels (Supplementary Fig. S7a) 236 even in relation to the number of smoked cigarettes per day (Supplementary Fig. S7b and S6). On the contrary, BMI, which was not influencing the frequency of IgG positive individuals, was affecting 237 238 the plasma concentration of IgG: the higher the BMI, the higher the level of IgG (Supplementary 239 Table S6, p = 0.0009)

240

241 IgG plasma levels and symptoms

242 As we have shown that the distribution of the IgG positive (>12 AU/mL) population followed a 243 sigmoidal curve with a constant level of individuals up to 7 concomitant symptoms, we thus evaluated 244 whether there was also a correlation between the plasma level of IgG and the number of symptoms. 245 The distribution of IgG levels in the population versus the cumulative symptoms was very similar 246 when analyzing the whole population or those of ICH and Gavazzeni which had different proportions of IgG positive individuals (Supplementary Fig. S8). They were characterized by similar areas under 247 the curve (All: 571; ICH: 550; Gavazzeni: 522) and the respective Receiver Operating Characteristics 248

249 (ROC) curves were perfect (100%), confirming maximal specificity and sensitivity of the IgG test at 250 IgG >12 AU/mL (Supplementary Fig. S8). Interestingly, we observed a direct correlation between 251 the number of concomitant symptoms and an increase in the level of plasma IgG (Fig. 5a, 252 Supplementary Table S7; CI are reported in the table for the different symptoms and combinations thereof, p < 0.014). By contrast, the level of IgG in the population with values < 12 AU/mL was 253 254 constant, regardless of the number of symptoms (Fig. 5b). When we analyzed the levels of IgG in 255 relation to symptoms, we found that those subjects reporting fever, anosmia/dysgeusia, or pneumonia 256 had all significant odds ratios (Fig. 5c). In addition, subjects with fever, cough, muscular pain, 257 asthenia, anosmia/dysgeusia, dyspnea, chest pain, tachycardia or pneumonia, they all had higher IgG 258 levels than those without symptoms (Supplementary Table S7, p values and CI are reported in the table for the different symptoms). This confirms that presence of symptoms correlates with higher 259 260 IgG levels as shown in Fig. 5a. Further, combination of fever with anosmia/dysgeusia and/or dyspnea 261 characterized populations with higher IgG plasma levels (Supplementary Table S7, p<0.0001, CI are 262 reported in the table for the different symptoms and combinations thereof), also when considering the 263 whole population regardless of IgG positivity (Fig. 5d, p<0.0001 in a LR test for global null 264 hypothesis ordinal logistic analysis). When considering the level of IgG ≥12 the distribution of IgG 265 plasma levels was very similar in subjects with these symptoms (Fig. 5e), however we found 266 statistically significant differences in odds ratios when combining fever with anosmia/dysgeusia and 267 fever with anosmia/dysgeusia and dyspnea (Fig. 5f, p=0.0004 in a LR test for global null hypothesis 268 ordinal logistic analysis). This confirms that these symptoms are the ones best characterizing SARS-269 CoV-2 infection. No statistically significant differences in IgG plasma levels were observed in 270 relation to comorbidities. In steatosis/cirrhosis we had only two cases in which we found an inverse 271 correlation but this should be confirmed on a higher number of individuals (p=0.0211, CI 12.30-272 12.70, Supplementary Table S8). Moreover, we observed an interesting inverse correlation between 273 pneumococcal vaccination and IgG plasma levels (p=0.03, CI 15-29.40, Supplementary Table S9).

274 **Discussion**

Here we report a comprehensive analysis of nearly 4000 individuals from different healthcare 275 276 facilities representative of dramatically different levels of SARS-CoV-2 exposure in Lombardy, the 277 most affected region by COVID-19 in Italy. We observed a range of positivity which strongly 278 correlated with the geographical area of viral exposure from 3% in the Varese area to 43% in the 279 Bergamo area, which were respectively the most or less COVID-affected Lombardy provinces. The 280 proportion of IgG positive females was higher than that of males in all of the analyzed sites. However, 281 we found a lower proportion of IgG positive individuals in females older than 60 years old than in age-matched males. This is guite intriguing as males and females are equally affected by COVID-19. 282 but males have a worse prognosis ¹⁶. Through the use of a quantitative antibody test of IgG we were 283 284 also able to assess the magnitude of the immune response. We found that younger males (below 40 285 yo) displayed reduced IgG plasma levels than older males (from 41 yo onwards). This is in line with a recent report in COVID-19 patients showing that younger patients developed lower titers of IgG¹⁷ 286 287 and another one showing that higher IgG titers in the plasma of convalescent individuals were 288 associated to older age and male sex ¹⁸. Thus, also in the healthy population, younger males exposed 289 to the virus develop a reduced antibody response. Hence, it is very important when analyzing the 290 serology to SARS-CoV-2 to take into account both age and sex.

Our study differs from the one reported by Sood and colleagues in Los Angeles County¹⁹ as we used a quantitative antibody test and analyzed a large hospital population which ranged from healthcare professionals, researchers and administrative staff from 7 different facilities. Indirectly, we show that it is rather the environment than the hospital professional exposure which dictates the probability of contracting SARS-CoV-2 infection. Indeed, we show a higher percentage of IgG positive individuals in areas with a higher incidence of COVID-19 and among subjects who had been in contact with COVID-19 affected relatives. Further, we observed a similar proportion of IgG positive individuals

298 among healthcare professionals functioning at hospital and administrative staff working from home. 299 However, the magnitude of the antibody response in terms of plasma levels of IgG was higher in 300 healthcare professionals suggesting that these individuals developed a more sustained immune 301 response. We were also able to pinpoint 11.9% of IgG positive individuals which were completely asymptomatic and another 23.1% of paucisymptomatic subjects with 1 or 2 symptoms. This 302 303 percentage differs from that observed in two recent studies analyzing SARS-CoV-2 infection via viral testing across different population types ^{20,21}. Among healthcare workers, 57% of the subjects were 304 305 asymptomatic/paucisymptomatic²⁰ while in a wider population in the Italian municipality of Vo' 306 Euganeo, that underwent lockdown soon after detecting the first case of COVID-19, the percentage of asymptomatics was 42.5²¹. This suggests that there is still a good proportion of individuals that 307 308 probably do not develop antibodies, or develop them at low/undetectable levels. This would be in line with recent studies showing that IgG positivity is short-lived ²² and relatives of COVID-19 patients 309 310 carry T cells specific for SARS-CoV-2 but do not seroconvert, suggesting that also IgG positivity 311 may not detect all individuals exposed to the virus ²³. However, if we expand our analysis to 312 healthcare workers without symptoms but with IgG >3.8 AU/mL, and not simply those IgG ≥ 12 313 AU/mL, which are considered 'positive' by the manufacturer of the test, the percentage of positivity 314 raises to 40%. This may indicate that there may be different exposures to the virus which result in a 315 wide range of levels of antibody production, including those between 3.8 and 12 AU/mL. As in 283 316 subjects with IgG 3.8-12 AU/mL we performed a viral test, and it was negative, this indicates that 317 they probably were exposed to the virus earlier and succeeded in eliminating it without a strong 318 antibody response. Thus, it would be interesting to evaluate which serology test was used and which 319 cut-off value was considered for determining IgG positivity in studies where IgG responses were negative, but T cell responses were present ²³. In addition, some of SARS-CoV-2 viral peptides 320 activated T cells also from unexposed individuals suggesting that some cross-reactivity could occur, 321 maybe in response to previous infections with common cold coronaviruses ²⁴. 322

Among the symptoms, those that characterized most the IgG positive population were fever and anosmia/dysgeusia. 81.2% of individuals presenting both anosmia/dysgeusia and fever resulted SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19.

Selected vaccines such as BCG have been suggested to increase pathogen-agnostic off-target resistance to infectious agents ²⁵. However, a recent report showed no differences in incidence of COVID-19 in BCG vaccinated versus non vaccinated patient population ²⁶. In line with this, we did not observe a correlation between IgG positivity and BCG vaccination.

330 Intriguingly, we observed an inverse correlation between induction of an antibody response and 331 smoking habit. This may indicate either a lower incidence of SARS-CoV-2 infection in smokers, or 332 their inability to induce an immune response to the virus. The former is more likely as a large study 333 (114,545 individuals) in Israel recently showed that the risk of SARS-CoV-2 positive testing in smoking individuals is reduced by half²⁷. When analyzing the concentrations of IgG in plasma, we 334 335 found no differences between males and females, nor in smoking habits. However, we observed that the presence of some symptoms such as fever, cough, muscular pain, astenia, anosmia/dysgeusia and 336 337 pneumonia correlated with higher levels of IgG than in subjects without these symptoms. In addition, 338 we found that the presence of comorbidities did not affect IgG plasma levels except for cirrhosis. 339 Subjects with cirrhosis had an inverse correlation with IgGs but the number of subjects was very low 340 and this finding needs to be confirmed. The significance of this is unknown, but the finding that cirrhotic patients have higher risk of severe COVID²⁸ may suggest that this condition may affect the 341 342 correct development of antibodies. Finally, we found that although very few subjects had anti-343 pneumoccocal vaccination, these had a reduced level of IgG, while there was no difference among 344 those vaccinated with flu vaccine. A recent study has shown an inverse correlation between 345 nasopharyngeal swab positivity and flu and pneumococcus vaccinations suggesting protection in 346 vaccinated individuals²⁹. Another report on the Italian population, based on regional and not on individual data, has shown an inverse correlation between COVID-19 cases and coverage of flu 347

348 vaccinations, suggesting again a protective role of flu vaccination ³⁰. It is possible that flu vaccination, 349 by inhibiting concomitant infection, may result in a better prognosis of the SARS-CoV-2 infected 350 individuals which becomes evident only when analyzing COVID-19 cases and not asymptomatic or 351 paucisymptomatic individuals. Why individuals vaccinated against pneumococcus should produce 352 less antibodies remains to be evaluated.

353

354 In conclusion, our study has some limitations, as it is monitoring healthcare workers, and thus it does 355 not reflect a comprehensive population as a good proportion of professionals are women and there is 356 an underrepresentation of the elderly due to working age limit. However, we show that antibody 357 testing can identify the individuals that were exposed to SARS-CoV-2 and is a powerful tool to 358 retrospectively evaluate viral diffusion, even in asymptomatic individuals. Another limitation of the 359 study is that we may have missed the population of subjects which do not develop an antibody 360 response or that is reduced over time. As our study is ongoing we will assess the evolution of the IgG response over a planned follow up of one year, allowing for measuring the duration of the antibody 361 362 response. Should a second wave of SARS-CoV-2 infection occur, the wide range of IgG serology in 363 the different sites will be particularly valuable as it will allow us to assess the role of antibodies in 364 viral protection. As we also collected the PBMC from a good proportion of our cohort, this will allow 365 us to evaluate whether the T cell response lasts longer than the B cell response and may highlight 366 individuals exposed to the virus which have not seroconverted, or whose level of antibodies was 367 below 12 AU/mL. The results presented here suggest that hospital health care professionals, 368 researchers and administrative staff can provide invaluable information to assess variables affecting 369 the immune response to SARS-CoV-2 as a snapshot and during the follow-up.

370

372 Methods

373 Clinical Study

The study has been approved by the international review board of Istituto Clinico Humanitas for all 374 participating institutes (clinicaltrial.gov NCT04387929). Accrual was on a voluntary basis: it started 375 376 on April 28th and more than 65% of employees participated as of May 16th, 2020. 7 different centers participated to the study: Istituto Clinico Humanitas (ICH), Rozzano, Mi; Humanitas Gavazzeni, 377 378 Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini (HMD), Castellanza (Va); 379 Humanitas Medical Center, HMC, Varese, Mi; Humanitas University, Pieve Emanuele (Mi); Humanitas San Pio X, Milano. All participants signed an informed consent and filled a questionnaire 380 381 (Supplementary Data S1) before blood collection. In order to be tested, subjects had to fill in the 382 questionnaire. Only after filling the questionnaire in its entirety, would the individuals be scheduled 383 for blood sampling. Hence, we obtained a 100% complete data.

All subjects with IgG > 12 AU/mL underwent a rinopharingeal swab for SARS-CoV-2 viral RNA
detection.

386

387 SARS-CoV-2 RT-PCR

Rinopharyngeal swab were tested with a commercial RT-PCR assay (AllplexTM2019-nCoV Assay
– Seegene, Seoul, South Korea), according to manufacturer's instruction. RNA extraction was
performed using Seegene Nimbus, a liquid handler workstation, Real-time PCR was run on a CFX96
TMDx thermocycler (Bio-Rad Laboratories, Inc, CA, USA) and subsequently interpreted by
Seegene's Viewer software. The test target three viral genes (*E, RdRp* and *N*).

393

394 IgG determination

For the determination of IgG anti SARS-CoV-2 the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia (VC), Italy) was used ³¹. The method is an indirect chemiluminescence immunoassay for the determination of anti-S1 and anti-S2 specific antibodies. Intra- and inter-assay coefficient of variation are <1.9% and <3.7% respectively. In the datasheet of the test, in a cohort of 304 COVID-19 patients 97.5% of the samples above 15 AU/mL and 86% of those with IgG>12 AU/mL resulted positive for neutralizing antibodies with a titer >1:40 in the Plaque Reduction Neutralization Test (PRNT).

402 The sensitivity of the test as reported by the manufacturer is 90.4% (79.4% - 95.8%) while the 403 specificity is 98.5% (97.5% - 99.2%).

404

405 Statistics

This was a cross sectional study aimed at determining the frequency of plasma anti- SARS-CoV-2
IgG antibodies in nearly 4000 (3985) employees of 7 different healthcare facilities located in
Lombardy.

The serological determination was offered to all the employees of the involved sites and the anticipated refusal rate was assumed to be 10-15%. The overall IgG positivity was assumed to be around 10-15% (between 400-600 subjects).

412 Primary endpoint was the number of test positive subjects. Given the study size, the study was able 413 to estimate the overall positivity with a width of 95% confidence interval equal to 2% and the 414 positivity for subgroups of at least 200 patients with a width of 95% confidence interval equal to 9%. 415 No power analysis was performed to calculate the sample size.

416 As secondary endpoints we aimed to investigate the factors associated to plasma anti-SARS-CoV-2417 IgG positivity.

418 Basic demographic characteristics, including age, sex, smoking status, comorbidities, previous 419 vaccinations and symptoms were recorded and their association with IgG positivity was tabulated in 420 contingency tables and described by means of relative and absolute frequencies.

The association between these characteristics and IgG positivity was assessed by univariate logistic model and measured with the odds ratio (OR) and 95% Confidence Interval (CI) for each factor. A multivariable analysis, was also performed in order to assess the effect of characteristics of interest after adjustment for the other variables.

Furthermore, since our data have clustered structures as patients were clustered within hospitals, a multilevel model was also used to analyse data. The binary outcome (positive vs. negative serological assessment) was chosen and analysis was approached with a generalized linear model with the logic link, which is the logistic regression model. In our multilevel analysis there was a patient level and an hospital level.

We produced two models. In the first one we want to assess the effect of role, gender, age, BMI and cigarette smoking on the risk of positive serology. We estimated a random intercept model for hospital profiling and treat the hospital effects as random effects only. The role of subjects was considered related to the hospital attributes, while the subject level attributes were age (grouped in >60, \leq 60 years) and gender, BMI (\leq 20, \leq 25, \leq 30, \leq 35, >35) and number of smoked cigarettes/day (no, \leq 10, \leq 20 >20). BMI and cigarette smoking were considered as continuous variables. The others variables are all categorical. The interaction term of age*gender was included in the model.

In the second one we explored the relationship between vaccinations, symptoms and serological positivity, after adjustment for the previous factors, still considering a hierarchical model. This was obtained adding the symptoms, defined as binary variables, to the previous models. Summary statistical measures were the odds ratio with relative confidence interval. SAS GLIMMIX procedure (SAS© 9.4 release) was used for the purpose of analysis.

The same approach was used also for analysis of plasma levels. SAS Mixed procedure (SAS© 9.4
release) was used for the purpose of analysis.

Kruskal–Wallis and non-parametric tests for trend (Cuzick's and Mantel-Haenzel test, when
appropriate) have been used for multiple comparisons using Prism 8 Graphpad. For plasma levels,
odds ratio and relative 95%CI based on Wald Test presented in the figures were calculated using
logistic model applied to ordinal data.

448

449 Data availability

450 Data supporting the findings of this study are available within the paper and its Supplementary
451 Information files. All other data are available from the corresponding author upon reasonable
452 requests.

453

454 **References**

- 455 1 Wang, W. *et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens.
 456 *JAMA*, doi:10.1001/jama.2020.3786 (2020).
- 457 2 Xie, X. *et al.* Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT458 PCR Testing. *Radiology*, 200343, doi:10.1148/radiol.2020200343 (2020).
- 459 3 Ai, T. *et al.* Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019
 460 (COVID-19) in China: A Report of 1014 Cases. *Radiology*, 200642,

461 doi:10.1148/radiol.2020200642 (2020).

- 462 4 Di Paolo, M. *et al.* False-negative RT-PCR in SARS-CoV-2 disease: experience from an
 463 Italian COVID-19 unit. *ERJ Open Res* 6, doi:10.1183/23120541.00324-2020 (2020).
- Li, Y. *et al.* Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients
 clinically diagnosed with COVID-19. *J Med Virol* 92, 903-908, doi:10.1002/jmv.25786
 (2020).
- 467 6 Lippi, G., Simundic, A. M. & Plebani, M. Potential preanalytical and analytical
 468 vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin*469 *Chem Lab Med*, doi:10.1515/cclm-2020-0285 (2020).

Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat

Med, doi:10.1038/s41591-020-0897-1 (2020).

472	8	Xiang, F. et al. Antibody Detection and Dynamic Characteristics in Patients with COVID-
473		19. Clin Infect Dis, doi:10.1093/cid/ciaa461 (2020).
474	9	Huan Ma, W. Z., Hongliang He, Dan Zhao, Yunru Yang, Dehua Jiang, Peigen Yingjie,
475		Weihuang He, Changcheng Zhao, Ruting Yi, Xiaofang Wang, Bo Wang, Yuanhong Yun
476		Yang, Arnaud John Kombe Kombe, Chengchao Ding, Jiajia Xie, Yong Gao, Linzhao
477		Cheng1, Yajuan Li, Xiaoling Ma, Tengchuan Jin. COVID-19 diagnosis and study of serum
478		1 SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis.
479		MedRXiv, doi: https://doi.org/10.1101/2020.04.17.20064907 (2020).
480	10	Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature,
481		doi:10.1038/s41586-020-2196-x (2020).
482	11	B, L. Serology characteristics of SARS-CoV-2 infection since the exposure and post
483		symptoms onset. doi:10.1101/2020.03.23.20041707.
484	12	Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease
485		2019. Clin Infect Dis, doi:10.1093/cid/ciaa344 (2020).
486	13	Dioscoridi, L. & Carrisi, C. Covid-19 exposure risk for family members of healthcare
487		workers: an observational study. Int J Infect Dis, doi:10.1016/j.ijid.2020.06.106 (2020).
488	14	Onder, G., Rezza, G. & Brusaferro, S. Case-Fatality Rate and Characteristics of Patients
489		Dying in Relation to COVID-19 in Italy. JAMA, doi:10.1001/jama.2020.4683 (2020).
490	15	Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus
491		Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From
492		the Chinese Center for Disease Control and Prevention. JAMA, doi:10.1001/jama.2020.2648
493		(2020).
494	16	Jin, J. M. et al. Gender Differences in Patients With COVID-19: Focus on Severity and
495		Mortality. Front Public Health 8, 152, doi:10.3389/fpubh.2020.00152 (2020).
496	17	Wu, F. W., A, Liu, M. Wang, O, Chen, J,Jinghe Huang. Neutralizing antibody responses
497		to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. MedXriv,
498		doi:10.1101/2020.03.30.20047365 (2020).
499	18	Klein, S. et al. Sex, age, and hospitalization drive antibody responses in a COVID-19
500		convalescent plasma donor population. medRxiv, doi:10.1101/2020.06.26.20139063 (2020).

- Sood, N. *et al.* Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los
 Angeles County, California, on April 10-11, 2020. *JAMA*, doi:10.1001/jama.2020.8279
 (2020).
- 50420Rivett, L. *et al.* Screening of healthcare workers for SARS-CoV-2 highlights the role of505asymptomatic carriage in COVID-19 transmission. *Elife* 9, doi:10.7554/eLife.58728 (2020).
- 506 21 Lavezzo, E. *et al.* Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'.
 507 *Nature*, doi:10.1038/s41586-020-2488-1 (2020).
- 508 22 Ni, L. *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in
- 509 COVID-19 Convalescent Individuals. *Immunity* **52**, 971-977 e973,
- 510 doi:10.1016/j.immuni.2020.04.023 (2020).
- 511 23 Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with
- 512 COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415,

513 doi:10.1016/j.cell.2020.05.015 (2020).

- 514 24 Weiskopf, D. *et al.* Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19
 515 patients with acute respiratory distress syndrome. *Sci Immunol* 5,
- 516 doi:10.1126/sciimmunol.abd2071 (2020).
- 517 25 Netea, M. G. *et al.* Defining trained immunity and its role in health and disease. *Nat Rev*518 *Immunol*, doi:10.1038/s41577-020-0285-6 (2020).
- 519 26 Hamiel, U., Kozer, E. & Youngster, I. SARS-CoV-2 Rates in BCG-Vaccinated and
 520 Unvaccinated Young Adults. *JAMA*, doi:10.1001/jama.2020.8189 (2020).
- 521 27 Israel, A., Feldhamer, I, Lahad, A, Levin-Zamir, D, and Lavie, G. Smoking and the risk of
 522 COVID-19 in a large observational population study. *MedrXiv*, doi:
 523 https://doi.org/10.1101/2020.06.01.20118877 (2020).
- 524 28 Iavarone, M. *et al.* High rates of 30-day mortality in patients with cirrhosis and COVID-19.
 525 *J Hepatol*, doi:10.1016/j.jhep.2020.06.001 (2020).
- 526 29 Noale, M. *et al.* The Association between Influenza and Pneumococcal Vaccinations and
- 527 SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey. *Vaccines (Basel)*528 8, doi:10.3390/vaccines8030471 (2020).
- 529 30 Amato, M. et al. Relationship between Influenza Vaccination Coverage Rate and COVID-
- 530 19 Outbreak: An Italian Ecological Study. Vaccines (Basel) 8,
- 531 doi:10.3390/vaccines8030535 (2020).

Bonelli, F. *et al.* Clinical And Analytical Performance Of An Automated Serological Test
 That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively. *J Clin Microbiol*, doi:10.1128/JCM.01224-20 (2020).

535

536 Acknowledgments

537 This work was partially supported by a philantropic donation by Dolce & Gabbana and by the Italian

538 Ministry of Health (Ricerca corrente).

We would like to thank all the employees that volunteered to participate to this study, all the nurses and personnel that collected the samples and the laboratory technicians that run the serological and rinopharyngeal tests. We would also like to thank the Humanitas management and staff, Dr Patrizia Meroni, who warmly supported this study for the safety of the employees. Dr Alice Bertocchi for critical reading of the manuscript.

544

545 Author contribution

M.T.S. coordinated the laboratory analyses and helped writing the manuscript; E.A.: coordinated the recruitment and sampling of subjects and participated in clinical study design; V.T.: performed the statistical analysis and helped writing the manuscript; S.C.: helped in analyzing the data; C.P.: contributed to data analysis and manuscript writing; M.S.: carried out the laboratory analyses; M.T.: participated in writing the clinical protocol; M.C.: coordinated the study for the Bergamo sites; A.M.: helped writing the manuscript and designing the study protocol; M.R.: conceived the study, analyzed the data and wrote the manuscript.

553

554 **Competing interests**

555 The authors declare no competing interests.

557 Figure legends

Figure 1. Distribution of IgG positivity (≥12 AU/mL) across different geographical areas and healthcare facilities in Lombardy, Italy.

Employees from 7 different healthcare facilities were analyzed for their anti-SARS-CoV-2 IgG positivity. Pie charts show the percentage of negative subjects (IgG <12 AU/mL) (orange) and that of positive subjects (IgG \geq 12 AU/mL) (blue) in each site: Istituto Clinico Humanitas (ICH), Rozzano (MI); Humanitas Gavazzeni, Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini

564 (HMD), Castellanza (VA); Humanitas Medical Center (HMC), Varese (VA); Humanitas University

565 (HU), Pieve Emanuele (MI); Humanitas San Pio X, Milan, (MI).

566

567 Figure 2. Frequency of IgG positivity (IgG \ge 12 AU/mL) by age.

a, b, Histograms show the number (a) and the percentage (b) of positive individuals (IgG ≥ 12 AU/mL) divided by age range and sex on the whole population regardless of site; in b, *p*-values were determined using Cuzick's test for trend. p = 0.0374 (total); p = 0.0008 (female); p = 0.1498 (male); p = 0.0024 (interaction).

572

573 Figure 3. Distribution of the IgG \geq 12 and IgG<12 populations versus the number of symptoms


a, c, Distribution of the IgG positive individuals (IgG \ge 12 AU/mL) as number of individuals (a) or percentage of the population (c) versus the number of self-reported symptoms. The curve that best interpolated the data was a sigmoidal, four parameter logistic curve whereby X is the number of symptoms (R²=0.97). b, d, Distribution of the IgG negative individuals (IgG < 12 AU/mL) as number of individuals (b) or percentage of the population (d) versus the number of self-reported symptoms. The curve that best interpolated the data was exponential (R²=0.9975).


581 Figure 4. Distribution of IgG plasma levels in the different populations.

a, Distribution of IgG plasma levels in the cohort of IgG positive individuals (IgG \ge 12 AU/mL) negative or positive for the rinopharyngeal swab or ascertained COVID-19 disease. b, Distribution of IgG plasma levels in IgG positive individuals (IgG \ge 12 AU/mL) divided by sex. c, Distribution of IgG plasma levels in IgG positive individuals (IgG \ge 12 AU/mL) divided by age ranges and sex. In a and b *p*-values were determined using Cochran Mantel-Haenzel test for trend. In c, Cuzick's test for trend was used: *p* = 0.0002 (total); *p* = 0.0085 (female); *p* = 0.008 (male); *p* = 0.4192 (interaction).

589 Figure 5. Distribution of IgG plasma levels in relation to symptoms

590 a, Distribution of IgG plasma levels versus the number of self-reported symptoms in IgG positive 591 individuals (IgG \geq 12 AU/mL). b, Distribution of IgG plasma levels versus the number of self-592 reported symptoms in IgG negative individuals (IgG < 12 AU/mL). c, Association between symptoms 593 and IgG plasma levels. p<0.0001, LR test for global null hypothesis. Odds ratio (OR) calculated with 594 logistic regression for ordinal data. d. Analysis of plasma levels of the whole population in relation 595 to a combination of symptoms, p < 0.0001. Odds ratio (OR) calculated with logistic analysis for 596 ordinal data. e, Distribution of IgG plasma levels versus selected symptoms (alone or in combination) 597 in individuals with IgG \geq 12 AU/mL. *p*-values evaluated using Kruskal–Wallis test with Dunn's post-598 hoc test. f, Analysis of plasma levels of positive subjects (IgG≥12) in relation to a combination of 599 symptoms, p=0.0004. Odds ratio (OR) calculated with logistic analysis for ordinal data.





b




Figure 2








Figure 3














IgG levels by age Males IgG ≥ 12





Figure 4







е

а











d


b

Odds Ratios with 95% Wald Confidence Limits



Odds Ratios with 95% Wald Confidence Limits








Figure 5

f